Bris­tol My­ers adds to neoad­ju­vant win for Op­di­vo in lung can­cer, es­ca­lat­ing ear­ly can­cer show­down with Mer­ck

Bris­tol My­ers Squibb and Mer­ck are locked in a heat­ed race to bring their block­buster PD-(L)1 drugs in­to ear­ly can­cer pa­tients as part of po­ten­tial­ly cu­ra­tive com­bi­na­tions. The ap­provals have been com­ing fast and heavy, and Bris­tol My­ers keeps adding to its case for a big-time FDA nod in lung can­cer.

A com­bi­na­tion of Op­di­vo and chemo in the neoad­ju­vant set­ting be­fore surgery cut the risk of re­cur­rence or death in pa­tients with stage IB to II­IA non-small cell lung can­cer over pre-surgery chemo alone, ac­ing the sec­ond pri­ma­ry end­point in the Phase III CHECK­MATE-816 study, Bris­tol My­ers said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.